Recursion Pharmaceuticals EPS Diluted (Quarterly) Analysis

Recursion Pharmaceuticals Inc (RXRX)

5.695 -0.06 (-0.96%) USD | NASDAQ | Nov 22, 16:00

5.75 +0.06 (+0.97%) After-Hours: 19:26

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2020. Upgrade now.

Date	Value
September 30, 2024	-0.34
June 30, 2024	-0.40
March 31, 2024	-0.39
December 31, 2023	-0.42
September 30, 2023	-0.43
June 30, 2023	-0.38
March 31, 2023	-0.34
December 31, 2022	-0.31
September 30, 2022	-0.35
June 30, 2022	-0.38

Date	Value
March 31, 2022	-0.33
December 31, 2021	-0.38
September 30, 2021	-0.28
June 30, 2021	-0.31
March 31, 2021	-0.197
December 31, 2020	-0.2291
September 30, 2020	-0.2123
June 30, 2020	-0.1684
March 31, 2020	-0.1638

Earnings per Share Definition

Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.

Read full definition.

EPS Diluted (Quarterly) Range, Past 5 Years

-0.43

Minimum

Sep 2023

-0.1638

Maximum

Mar 2020

-0.3163

Average

-0.34

Median

Mar 2023

EPS Diluted (Quarterly) Benchmarks

Revance Therapeutics Inc	-0.37
NovaBay Pharmaceuticals Inc	-0.60
Palatin Technologies Inc	-0.39
iBio Inc	-0.46
Theriva Biologics Inc	-6.81

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly)	-95.84M
Revenue (Quarterly)	26.08M
Total Expenses (Quarterly)	124.44M
Enterprise Value	1.249B
Gross Profit Margin (Quarterly)	53.69%
Profit Margin (Quarterly)	-367.5%
Earnings Yield	-27.22%
Normalized Earnings Yield	-27.22